retatrutide weight loss trials results ๐ may be redefining obesity treatment. New data from TRIUMPH-1 Trial showed: ๐ฅ ~28% average over 80 weeks ๐ฅ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Eli Lilly's Retatrutide Phase 3
Description
Key findings of the study: After weighting, the researchers found that the use of GLP-1 receptor agonists was associated with lower all-cause mortality (hazard ratio [HR], 0.79) and lower sepsis- and infection-related mortality (HR, 0.61)
Axe content is medically reviewed or fact checked to ensure factually accurate information
[DOI] [PubMed] [Google Scholar] 83.Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, et al
Addressing those contributors, while using a GLP-1 as a supportive tool, can improve both results and durability
Enter GLP-1 support gummiesa sweeter, over-the-counter pitch that claims similar appetite control with fiber, berberine, or probiotics
why teens often enter ketosis faster than adults
